Navigation Links
The Leukemia & Lymphoma Society Co-Pay Assistance Fund Surpasses $200 Million
Date:8/21/2013

WHITE PLAINS, N.Y., Aug. 21, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is proud to announce that it has raised more than $200 million in funding for its Co-Pay Assistance Program since its inception in 2007.

The program provides support for prescription drug co-pays and health insurance premiums for blood cancer patients who meet certain income requirements. Patients with private insurance, Medicare beneficiaries under Medicare Part B and/or Medicare Plan D, Medicare Supplementary Health Insurance and Medicare Advantage are eligible.

To date, LLS has helped approximately 36,000 patients through the co-pay program.

"Receiving a diagnosis of a blood cancer can be overwhelming for a patient, and such devastating news can be compounded by an inability to afford the treatments," said John Walter, LLS president and CEO. "LLS's Co-Pay Assistance Program helps alleviate this burden for eligible patients and their families. LLS exists, not only to find cures, but also to ensure access to the best available therapies for all blood cancer patients, and helping patients afford their treatments is a critical part of our mission."

Patients, caregivers, pharmacies and healthcare providers can easily submit online co-pay applications with a quick registration process, day or night. Doctors, treatment providers or pharmacies can apply for the program on behalf of their patients.

Visit www.lls.org/copay or call 877-LLS-COPAY to learn more about the program and which blood cancers are currently covered.

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.  

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org.  Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

Contact: Andrea Greif
(914) 821-8958, (914) 772-3027 (cell)
andrea.greif@lls.org

 


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
2. Celebrating 25 Years and Counting: Leukemia and Lymphoma Societys "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients
3. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
4. The Leukemia & Lymphoma Society and Dana-Farber Cancer Institute to Bring Clinical Trials to Local Communities
5. The Leukemia & Lymphoma Society Applauds FDAs Approval of Lenalidomide for Patients with Relapsed or Refractory Mantle Cell Lymphoma
6. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
7. Leading Leukemia Experts: High Leukemia Treatment Costs May Be Harming Patients
8. Tosedostat OPAL Study in Acute Myeloid Leukemia Published in Lancet Oncology
9. Launch Of Premium-priced, Novel Targeted Therapies Will Drive Growth In The Acute Leukemia Markets Beginning In 2015
10. The Leukemia & Lymphoma Society and Avella Specialty Pharmacy to Present Free Event on Oral Chemotherapy Drugs
11. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... The vast majority of dialysis patients currently ... are usually 3 times a week, with treatment times ... time, equipment preparation and wait time.  This regimen can ... patients who are elderly and frail.  Many elderly dialysis ... centers for some duration of time. Residents ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... rough waters, but it continues to present great opportunities ... featured companies for today: Intrexon Corp. (NYSE: ... ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), ... Learn more about these stocks and receive your complimentary ...
(Date:6/23/2016)... -- Delcath Systems, Inc. (NASDAQ: DCTH ), a ... of primary and metastatic liver cancers, announces that the ... www.againsttheodds.eu - has been awarded a silver medal ... The website was developed as an education ... who are coping with the devastating diagnosis of cancer ...
Breaking Medicine Technology:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... for human induced pluripotent stem (iPS) cells and other difficult to transfect cells, ... Cloning Medium. The PluriQ™ G9™ Gene Editing System is a complete ...
(Date:6/24/2016)... ... June 24, 2016 , ... Finally, a bruise cream ... procedures, dermaka cream can be incorporated into the post-surgical treatment plans of a variety ... , dermaka cream is very effective for bruising and causes a rapid resolution ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Randall Markarian, DDS, are co-chairs for the Illinois State Dental Society (ISDS) Foundation’s ... 15-16 at the Gateway Convention Center in Collinsville. , They expect ...
(Date:6/24/2016)... ... June 24, 2016 , ... SpiritQuest Sedona Retreats, located in ... Sedona, surrounded by famous vortex sites: Cathedral Rock, Airport Mesa, and Boynton Canyon. The ... the Lodge at Sedona as well as the Sedona Rouge, both popular accommodations for ...
(Date:6/23/2016)... ... June 23, 2016 , ... Terumo BCT, a global ... for clinical transfusion research programs and for the blood supply in the Netherlands, ... Predictive Analytical Rating Score (PREPAReS) study. , Currently in its sixth year, ...
Breaking Medicine News(10 mins):